Abstract

The neuromuscular junction (NMJ) serves as a fundamental interface for synaptic communication, facilitating the transmission of electrical signals from nerves to muscles. This review explores the pivotal role of the NMJ in coordinating muscle function and highlights recent advances in understanding its molecular architecture and physiological mechanisms. Key components of the NMJ, including presynaptic motor nerve endings, the synaptic cleft, and postsynaptic muscle membranes, are discussed in detail, emphasizing their roles in neurotransmitter release, signal transduction, and muscle contraction. Nicotinic acetylcholine receptors (nAChRs), crucial mediators of neuromuscular transmission, are examined with respect to their structural diversity, subunit composition, and physiological functions. Furthermore, distinct mechanisms of action and clinical implications of neuromuscular blocking agents (NMBAs) in neuromuscular transmission are elucidated, encompassing both non-depolarizing and depolarizing agents. Additionally, physiological alterations and pathological conditions affecting neurotransmission at the NMJ are addressed, including botulism, Lambert-Eaton syndrome, neuromyotonia, and myasthenia gravis, along with the potential implications for NMBA use in clinical settings. Furthermore, the involvement of nicotinic receptors in vital regulatory systems such as inflammation and oxygen sensing underscores their clinical relevance beyond neuromuscular transmission. Overall, this review provides comprehensive insights into the NMJ's role in neuromuscular function, the pharmacology of NMBAs, and their clinical implications in various medical conditions. review provides comprehensive insights into the NMJ's role in neuromuscular function, the pharmacology of NMBAs, and their clinical implications in various medical conditions.

Keywords

Introduction

The neuromuscular junction (NMJ) stands as a cornerstone in synaptic research, offering valuable insights into how electrical signals propagate and communicate between neurons and effector cells throughout the nervous system. This phenomenon, often termed neurotransmission, involves both electrical and chemical processes crucial for transmitting information from nerve to muscle [1, 2]. Claude Bernard's pioneering studies on the effects of curare on nerve-muscle preparations marked the initial understanding of electrical neurotransmission and the role of chemical compounds in this process [3]. Initially, Bernard attributed curare's effect to a direct action on the nerve, overlooking the possibility of a specific junction between nerve and muscle [4, 5]. However, later investigations by Vulpian and Langley confirmed the existence of such a junction, elucidating the role of chemical compounds released by the nerve and transmitted across the NMJ to initiate muscle contractions [6, 7]. Recent research in this field, which we will explore in this review, holds clinical significance, particularly in advancing our comprehension of neuromuscular blocking agents (NMBAs), neuromuscular monitoring, and the management of neuromuscular disorders in anesthesia and intensive care settings.

The Role of the Neuromuscular Junction in Coordinated Muscle Function

The neuromuscular junction (NMJ) plays a vital role in transmitting electrical impulses from nerves to muscles, enabling precise muscle contractions. Its intricate structure involves specialized areas facilitating the controlled release of neurotransmitters, essential for efficient neurotransmission [8, 9] .Comprising the presynaptic motor nerve ending, the synaptic cleft, and the postsynaptic muscle membrane, the NMJ ensures swift transmission of information through the release of acetylcholine (ACh) and activation of nicotinic acetylcholine receptors (nAChRs) [10, 11] .The presynaptic part, encompassing the distal motor neurone and terminal Schwann cell, anchors the nerve ending to the muscle membrane and supports nerve-muscle connectivity. Although not directly involved in chemical transmission, Schwann cells aid in maintaining the nerve terminal and promoting nerve regeneration [12, 13]. The nerve terminal, housing cholinergic autoreceptors, orchestrates neurotransmitter release and sustains junctional architecture, powered by mitochondria. ACh synthesis, storage, and release by the nerve terminal are essential for neurotransmission. The mechanisms underlying ACh packaging into vesicles remain partially understood, with vesicles stored near the presynaptic cell membrane for rapid release [14, 15]. Upon arrival of an action potential, calcium influx triggers vesicle fusion and neurotransmitter release into the synaptic cleft, initiating muscle depolarization. The synaptic cleft, spanning approximately 50 nm, contains molecules such as acetylcholinesterase, which degrade ACh, terminating its action [16, 17]. The postsynaptic membrane, with primary and secondary folds hosting dense nAChR clusters, facilitates efficient signal transduction and muscle contraction. The perijunctional zone, rich in sodium channels, amplifies depolarization responses, promoting effective signal transmission into the muscle cell [18, 19]. Overall, the NMJ's complex architecture and molecular processes ensure precise communication between nerves and muscles, essential for coordinated movement and muscle function.

Fig. 1.  Mechanism of Neuromuscular Transmission

Nicotinic Acetylcholine Receptors: Key Regulators of Neurotransmission and Beyond

The neuromuscular junction (NMJ) is primarily regulated by nicotinic acetylcholine receptors (nAChRs), which serve as key players in fast neurotransmission. These receptors are found both pre- and postsynaptically and are activated by acetylcholine (ACh), facilitating rapid signal transmission [20, 21]. The nAChRs are extensively studied and serve as the archetype for the cys-loop superfamily of ligand-gated ion channels, which includes other receptors like GABAA, glycine, and 5-HT3 receptors [22, 23]. Structurally, they consist of five subunits forming a central pore, each subunit comprising four transmembrane segments with the second segment lining the pore. Upon ACh binding, the nAChRs allow the influx of cations, such as Na+ and Ca2+, leading to cell membrane depolarization. Traditionally, nAChRs were categorized into muscle and neuronal subtypes based on their predominant expression sites [24, 25]. However, recent evidence suggests that many neuronal nAChRs are also present in non-neuronal tissues. Currently, 17 nicotinic subunits have been identified, including muscle (?1, ?1, ?, ?, and ?) and neuronal (?2–?10 and ?2–?4) subunits. While ? subunits possess crucial cysteine residues for ACh binding, both ? and non-? subunits contribute to receptor subtype specificity [26, 27]. These subunits assemble to form muscular (?1?1?/?/?) and additionally, neuronal nAChRs play crucial roles in regulating functions such as behavior, cognition, memory, and vital control systems in the peripheral nervous system, including breathing regulation, inflammation modulation, and immune system regulation. neuronal (heteromeric and homomeric) nAChRs. Muscular nAChRs predominantly consist of ?1?1?/?/? subtypes, whereas neuronal nAChRs encompass both homomeric and heteromeric receptors. Heteromeric receptors typically consist of ?2–6 and ?2–4 subunits, with a common stoichiometry of 2? and 3?. Despite numerous possible combinations, only a select few neuronal nAChRs hold biological significance [28, 29]. These receptors are widely distributed throughout the human body, with various subtypes serving critical roles in diverse physiological functions. In the central nervous system, the ?4?2 nAChR is primarily associated with nicotine addiction, while ?3?4, ?3?2, and ?7 nAChRs are abundant in autonomic ganglia and the adrenal medulla [30, 31]. Specific neuronal nAChR subunits, such as ?3–?5, ?7, ?2, and ?4, are implicated in oxygen signaling from oxygen-sensing chemoreceptor type-1 cells in the carotid body. These receptors are integral to chemoreceptor signal transduction during hypoxia, transmitting information via the carotid sinus nerve to central respiratory circuits in the brain stem, thereby eliciting a hypoxic ventilatory response [32, 33]. Notably, the ?7 nAChR is also found in macrophages and plays a critical role in the cholinergic anti-inflammatory pathway, which forms part of the inflammatory reflex. This pathway involves the inhibition of cytokine release via activation of ?7 nAChRs on macrophages by efferent signals from the vagus nerve, triggered in response to cytokines activated by pathogens and ischemia [34, 35].

Role of presynaptic nAChRs:

Nicotinic autoreceptors are situated at the presynaptic nerve terminal and play a crucial role in augmenting the release of acetylcholine (ACh) into the synaptic cleft during high-frequency stimulation of the presynaptic nerve terminal. Unlike being inhibited by ?-bungarotoxin, this cholinergic receptor is affected by non-depolarizing neuromuscular blocking agents (NMBAs) and hexamethonium [36, 37]. Identified as the neuronal nicotinic acetylcholine receptor (nAChR) ?3?2, targeted pharmacological inhibition of this presynaptic receptor during high-frequency repetitive (tetanic) stimulation results in a characteristic tetanic fade phenomenon[38, 39].

This tetanic fade, observed under experimental conditions, mirrors the classical train-of-four (TOF) fade seen in clinical scenarios of non-depolarizing neuromuscular blockade [40]. It serves as an indicator of non-depolarizing neuromuscular block during neuromuscular monitoring. Recent findings have shown that unlike the depolarizing NMBA succinylcholine, non-depolarizing NMBAs used clinically inhibit this ?3?2 nAChR. Consequently, this inhibition accounts for the absence of TOF fade during depolarizing blockade [41].

Fig. 2.  Structure of the ?3, ?2 nAChR

Role of postsynaptic nAChRs:

Acetylcholine (ACh) released from the motor nerve terminal binds to nicotinic acetylcholine receptors (nAChRs) located on the postsynaptic membrane, initiating membrane depolarization and subsequent muscle contraction. There exist two distinct types of muscle nAChRs: the fetal ?1?1?? subtype and the adult ?1?1?? subtype. These receptors assemble in a ratio of 2:1:1:1 and necessitate the binding of two ACh molecules for activation. Notably, two binding sites with differing affinities are present: one at the a-d interface and another at the ?-? /? interface. During fetal development, the muscle predominantly expresses the ?1?1?? nAChR subtype [42, 43]. However, after birth, heightened depolarization prompts a significant increase in the transcription of the e subunit. This heightened expression of the e subunit competes with the g subunit for receptor assembly, leading to a transition to the adult muscle ?1?1?? nAChR subtype. These adult receptors tend to aggregate preferentially at the neuromuscular junction, exhibit increased stability against degradation, and demonstrate a swifter response to agonists compared to their fetal counterparts [44, 45]. Under normal physiological conditions in adulthood, the muscle membrane primarily expresses the ?1?1?? nAChR subtype. However, conditions such as immobilization, denervation, or inflammation can trigger the re-expression of the g subunit, which is typically confined to the muscle nucleus, at the muscle membrane [46, 47]. Additionally, animal studies have indicated the presence of the neuronal a7 nAChR subtype in the muscle membrane during both developmental stages and denervation, suggesting a potential role in endplate stabilization and synaptogenesis. In essence, three distinct nAChR subtypes are evident at the postsynaptic muscle membrane: the fetal ?1?1?? and adult ?1?1?? receptors, alongside the neuronal a7 subtype [48, 49].

Distinct Mechanisms of Action and Clinical Implications of Neuromuscular Blocking Agents in Neuromuscular Transmission

The two distinct classes of clinically utilized neuromuscular blocking agents (NMBAs) exert their effects on neuromuscular transmission through different mechanisms. Non-depolarizing NMBAs, such as atracurium and rocuronium, have conventionally been characterized as competitive inhibitors of muscle nicotinic acetylcholine receptors (nAChRs). This entails their ability to compete with acetylcholine (ACh), the natural ligand, at the two binding sites of the nAChR [50, 51]. Clinically, this concept is reflected in the use of anticholinesterase agents to inhibit the degradation of ACh, thereby increasing its concentration and favoring neuromuscular transmission. Notably, a single molecule of non-depolarizing NMBA is sufficient to prevent receptor activation, contrasting with the requirement of two ACh molecules for activation, rendering NMBA inhibition preferable [52, 53]. Recent research suggests that the mechanism of inhibition of muscle nAChRs by non-depolarizing NMBAs may involve complexities beyond simple competitive inhibition. The clinical implications of this finding remain uncertain, necessitating further investigation. In the clinical context, the effects of non-depolarizing NMBAs manifest as a characteristic train-of-four (TOF) fade and a reduction in twitch amplitude, directly reflecting their action on different subtypes of nAChRs [54]. Inhibition of the presynaptic a3b2 nicotinic autoreceptor by non-depolarizing NMBAs contributes to TOF fade, while the reduction in twitch amplitude results from inhibition of muscle nAChRs at the postsynaptic muscle membrane. Thus, neuromuscular monitoring serves as the primary means to directly assess the effect of non-depolarizing NMBAs on target receptors [55, 56]. Conversely, a depolarizing NMBA such as succinylcholine reduces twitch amplitude but lacks TOF fade due to its distinct action at the muscle nAChR and low affinity for the presynaptic a3b2 nAChR. However, despite its extensive clinical use spanning over five decades, the exact mechanism of action of succinylcholine remains incompletely understood. Initial fasciculations observed post-administration reflect massive activation of muscle nAChRs at the postsynaptic muscle membrane, while subsequent paralysis likely involves receptor desensitization, inactivation of voltage-gated sodium channels, and increased potassium permeability in surrounding membranes [57, 58].

Physiological Alteration and Clinical Implications

Various medical conditions disrupt neurotransmission at the neuromuscular junction (NMJ) and affect the clinical use of neuromuscular blocking agents (NMBAs). Botulism, caused by botulinum toxin, results in flaccid paralysis due to the proteolytic cleavage of SNARE proteins crucial for acetylcholine (ACh) release from nerve endings [59, 60]. This inhibition of ACh release disrupts all ACh-releasing synapses, leading to muscle paralysis and potential cardiovascular complications [61]. Other disorders impacting the presynaptic site at the NMJ include Lambert-Eaton syndrome and neuromyotonia. Lambert-Eaton syndrome involves autoantibodies against P/Q-type voltage-gated calcium channels, resulting in muscle weakness, fatigue, and autonomic dysfunction. In contrast, autoantibodies against presynaptic potassium channels in neuromyotonia lead to increased presynaptic transmitter release and hyperexcitability, manifesting as severe muscle cramps, stiffness, and myokymia [62, 63]. Myasthenia gravis, the most prevalent disorder affecting the postsynaptic NMJ, involves autoantibodies against muscle nicotinic acetylcholine receptors (nAChRs), leading to muscle weakness. Increased presynaptic ACh release may partially compensate for the reduction in functional muscle nAChRs, but patients are often treated with anticholinesterases to enhance ACh levels and normalize synaptic function [64].

Furthermore, succinylcholine, a depolarizing NMBA, can induce severe hyperkalemia, potentially leading to malignant arrhythmias and cardiac arrest, particularly in patients with prolonged immobilization, inflammation, or denervation. This complication is attributed to upregulation of fetal and adult muscle nAChRs and extrajunctional expression of fetal muscle nAChRs induced by such conditions. During neuromuscular recovery, residual effects primarily affect respiratory and airway function [65, 66].

Non-depolarizing NMBAs not only reduce the acute hypoxic ventilatory response but also depress pharyngeal function and airway control, posing an increased risk for aspiration and airway impairment. Maintaining a train-of-four (TOF) ratio above 90?fore extubation is recommended to ensure adequate respiratory control and airway integrity. Additionally, the inhibitory effect of non-depolarizing NMBAs on neuronal nAChRs in the carotid body attenuates the hypoxic ventilatory response [67, 68]. The involvement of the ?7 nAChR in the cholinergic anti-inflammatory pathway may have clinical implications for the use of non-depolarizing NMBAs in conditions such as sepsis, hemorrhagic shock, and ischemia-reperfusion injury in the intensive care unit, given their inhibitory effect on this receptor [69, 70]. In summary, advancements in molecular biology and imaging techniques have enhanced our understanding of NMJ structure and function. Current knowledge of receptor physiology and pharmacology informs the action of NMBAs and underpins principles of neuromuscular monitoring. Additionally, it provides insight into the interaction between NMBAs and vital regulatory systems involved in respiration, inflammation, and the immune response.

CONCLUSION:

The neuromuscular junction (NMJ) serves as a critical interface for synaptic communication, facilitating the transmission of electrical signals from nerve to muscle. Through a complex interplay of molecular processes, including neurotransmitter release and receptor activation, precise muscle contractions are orchestrated. Recent research elucidates the intricate architecture and functioning of the NMJ, shedding light on its clinical relevance in areas such as anesthesia and intensive care. Key findings reveal the central role of nicotinic acetylcholine receptors (nAChRs) in fast neurotransmission at the NMJ. These receptors, comprising various subunits, mediate the rapid transmission of signals upon acetylcholine (ACh) binding, initiating muscle depolarization. Notably, their distribution extends beyond the neuromuscular context, influencing diverse physiological functions. Understanding the distinct mechanisms of action of neuromuscular blocking agents (NMBAs) provides crucial insights into their clinical implications. Non-depolarizing NMBAs competitively inhibit muscle nAChRs, leading to characteristic changes in neuromuscular monitoring, while depolarizing agents like succinylcholine exhibit unique effects on receptor activation. These pharmacological interventions have significant implications for patient care, particularly in anesthesia and critical care settings.

Physiological alterations affecting NMJ function, such as those seen in neuromuscular disorders and medical conditions, further underscore the clinical importance of NMJ research. Disorders impacting neurotransmission pathways highlight the delicate balance required for proper neuromuscular function and the potential consequences of disruption. Moreover, advancements in understanding the interaction between NMBAs and regulatory systems, such as the cholinergic anti-inflammatory pathway, broaden our perspective on their clinical use beyond neuromuscular blockade. Consideration of these interactions informs clinical decision-making and patient management strategies, particularly in contexts involving inflammation, immune response, and respiratory function. In summary, the comprehensive exploration of NMJ structure, function, and pharmacology enhances our understanding of synaptic transmission and its clinical implications. This knowledge serves as a foundation for improving patient care and developing novel therapeutic interventions targeting neuromuscular disorders and related conditions.

REFERENCES:

1. Gomez AM, Van Den Broeck J, Vrolix K, Janssen SP, Lemmens MA, Van Der Esch E, Duimel H, Frederik P, Molenaar PC, Martínez-Martínez P, De Baets MH. Antibody effector mechanisms in myasthenia gravis—pathogenesis at the neuromuscular junction. Autoimmunity. 2010 Aug 1;43(5-6):353-70.
2. Martyn JA, Fagerlund MJ, Eriksson LI. Basic principles of neuromuscular transmission. Anaesthesia. 2009 Mar;64:1-9.
3. Elliott TR, Dale HH. THE DISCOVERY OF CHEMICAL NEUROTRANSMISSION. A History of the Brain: From Stone Age surgery to modern neuroscience. 2014 Dec 8:289.
4. Barbara JG, Clarac F. Historical concepts on the relations between nerves and muscles. Brain research. 2011 Aug 29;1409:3-22.
5. Cousin MT. History of anaesthesia: who discovered the neuromuscular junction? The opposing views of Claude Bernard and Alfred Vulpian. European Journal of Anaesthesiology| EJA. 2013 Jan 1;30(1):1-4.
6. Langley JN, Anderson HK. The union of different kinds of nerve fibres. The Journal of physiology. 1904 Aug 8;31(5):365
7. Bennett MR. The concept of transmitter receptors: 100 years on. Neuropharmacology. 2000 Mar 15;39(4):523-46.
8. Arnold AJ, Razavieh A, Nasr JR, Schulman DS, Eichfeld CM, Das S. Mimicking neurotransmitter release in chemical synapses via hysteresis engineering in MoS2 transistors. ACS nano. 2017 Mar 28;11(3):3110-8.
9. Fagerlund MJ, Eriksson LI. Current concepts in neuromuscular transmission. British journal of anaesthesia. 2009 Jul 1;103(1):108-14.
10. Tomàs J, Santafé MM, Garcia N, Lanuza MA, Tomàs M, Besalduch N, Obis T, Priego M, Hurtado E. Presynaptic membrane receptors in acetylcholine release modulation in the neuromuscular synapse. Journal of Neuroscience Research. 2014 May;92(5):543-54.
11. Karlin A. Emerging structure of the nicotinic acetylcholine receptors. Nature Reviews Neuroscience. 2002 Feb 1;3(2):102-14.
12. Griffin JW, Thompson WJ. Biology and pathology of nonmyelinating Schwann cells. Glia. 2008 Nov 1;56(14):1518-31.
13. Zelada D, Bermedo?García F, Collao N, Henríquez JP. Motor function recovery: deciphering a regenerative niche at the neuromuscular synapse. Biological Reviews. 2021 Apr;96(2):752-66.
14. und Halbach OV, Dermietzel R. Neurotransmitters and neuromodulators: Handbook of receptors and biological effects. John Wiley & Sons; 2006 Dec 13.
15. Boff JM, Shrestha AP, Madireddy S, Viswaprakash N, Della Santina L, Vaithianathan T. The Interplay of Neurotransmitters and Calcium Dynamics in Retinal Synapses During Development, Health, and Disease.
16. Zimmerman G, Soreq H. Termination and beyond: acetylcholinesterase as a modulator of synaptic transmission. Cell and tissue research. 2006 Nov;326:655-69.
17. Bittner EA, Martyn JJ. Neuromuscular physiology and pharmacology. InPharmacology and Physiology for Anesthesia 2019 Jan 1 (pp. 412-427). Elsevier.
18. Huang CF, Flucher BE, Schmidt MM, Stroud SK, Schmidt J. Depolarization-transcription signals in skeletal muscle use calcium flux through L channels, but bypass the sarcoplasmic reticulum. Neuron. 1994 Jul 1;13(1):167-77.
19. Kannan M. Physiology and pharmacology of neuromuscular block. PONSZAC 2013 CME E-BOOK.:178.
20. Ruff RL. Neurophysiology of the neuromuscular junction: overview. Annals of the New York academy of sciences. 2003 Sep;998(1):1-0.
21. SYNAPTIC MT. Synaptic Transmission and the neuromuscular junction. Medical Physiology, 2e Updated Edition E-Book: with STUDENT CONSULT Online Access. 2012 Jan 13:212.
22. Connolly CN, Wafford KA. The Cys-loop superfamily of ligand-gated ion channels: the impact of receptor structure on function. Biochemical Society Transactions. 2004 Jun 1;32(3):529-34.
23. Reeves DC, Lummis SC. The molecular basis of the structure and function of the 5-HT 3 receptor: a model ligand-gated ion channel. Molecular membrane biology. 2002 Jan 1;19(1):11-26.
24. Dani JA. Neuronal nicotinic acetylcholine receptor structure and function and response to nicotine. International review of neurobiology. 2015 Jan 1;124:3-19.
25. Jensen AA, Frølund B, Liljefors T, Krogsgaard-Larsen P. Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. Journal of medicinal chemistry. 2005 Jul 28;48(15):4705-45.
26. Elgoyhen AB. The ?9?10 acetylcholine receptor: A non-neuronal nicotinic receptor. Pharmacological Research. 2023 Mar 15:106735.
27. Pakkanen J. Upregulation and Functionality of Neuronal Nicotinic Acetylcholine Receptors.
28. d'Incamps BL, Zorbaz T, Dingova D, Krejci E, Ascher P. Stoichiometry of the heteromeric nicotinic receptors of the Renshaw cell. Journal of Neuroscience. 2018 May 23;38(21):4943-56.
29. Borroni V, Barrantes FJ. Homomeric and heteromeric ?7 nicotinic acetylcholine receptors in health and some central nervous system diseases. Membranes. 2021 Aug 29;11(9):664.
30. McCorry LK. Physiology of the autonomic nervous system. American journal of pharmaceutical education. 2007 Aug 8;71(4).
31. Johnson JO. Autonomic nervous system: physiology. InPharmacology and physiology for anesthesia 2019 Jan 1 (pp. 270-281). Elsevier.
32. Kåhlin J. The Human Carotid Body: In Sensing and Signaling of Oxygen and Inflammation. Karolinska Institutet (Sweden); 2014.
33. Shirahata M. Neurotransmission in the carotid body and anesthesia. Journal of anesthesia. 2002 Nov;16:298-309.
34. Hoover DB. Cholinergic modulation of the immune system presents new approaches for treating inflammation. Pharmacology & therapeutics. 2017 Nov 1;179:1-6.
35. De Jonge WJ, Ulloa L. The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. British journal of pharmacology. 2007 Aug;151(7):915-29
36. Vizi ES. Interaction between adrenergic and cholinergic systems: presynaptic inhibitory effect of noradrenaline on acetylcholine release. InNeurovegetative Transmission Mechanisms: Proceedings of the International Neurovegetative Symposium, Tihany, June 19–24, 1972 1974 Jan 1 (pp. 61-78). Vienna: Springer Vienna.
37. Pereira MW, Correia?de?Sá P, Alves?Do?Prado W. Adenosine A 2A receptor antagonists are broad facilitators of antinicotinic neuromuscular blockade monitored either with 2 Hz train?of?four or 50 Hz tetanic stimuli. Clinical and Experimental Pharmacology and Physiology. 2012 Oct;39(10):869-77.
38. Faria M, Oliveira L, Timóteo MA, Lobo MG, Correia?de?sá P. Blockade of neuronal facilitatory nicotinic receptors containing ?3?2 subunits contribute to tetanic fade in the rat isolated diaphragm. Synapse. 2003 Aug;49(2):77-88.
39. Bowman WC. Prejunctional and postjunctional cholinoceptors at the neuromusclar junction. Anesthesia & Analgesia. 1980 Dec 1;59(12):935-43.
40. Schmartz D, Chénard L, Baumann C, Fuchs-Buder T. A modified train-of-four ratio to assess recovery from depolarizing neuromuscular blockade after succinylcholine, a prospective observational study. Journal of clinical monitoring and computing. 2021 Oct;35:1133-8.
41. Kim YB, Sung TY, Yang HS. Factors that affect the onset of action of non-depolarizing neuromuscular blocking agents. Korean journal of anesthesiology. 2017 Oct;70(5):500.
42. Cetin H, Beeson D, Vincent A, Webster R. The structure, function, and physiology of the fetal and adult acetylcholine receptor in muscle. Frontiers in molecular neuroscience. 2020 Sep 8;13:581097.
43. Bouzat C, Mukhtasimova N. The nicotinic acetylcholine receptor as a molecular machine for neuromuscular transmission. Current Opinion in Physiology. 2018 Aug 1;4:40-8
44. Cetin H, Beeson D, Vincent A, Webster R. The structure, function, and physiology of the fetal and adult acetylcholine receptor in muscle. Frontiers in molecular neuroscience. 2020 Sep 8;13:581097.
45. Kilbinger H. The autonomic cholinergic neuroeffector junction. The Cholinergic Synapse. 1988:581-95.
46. Cisterna BA, Vargas AA, Puebla C, Fernández P, Escamilla R, Lagos CF, Matus MF, Vilos C, Cea LA, Barnafi E, Gaete H. Active acetylcholine receptors prevent the atrophy of skeletal muscles and favor reinnervation. Nature communications. 2020 Feb 26;11(1):1073.
47. Kalamida D, Poulas K, Avramopoulou V, Fostieri E, Lagoumintzis G, Lazaridis K, Sideri A, Zouridakis M, Tzartos SJ. Muscle and neuronal nicotinic acetylcholine receptors: structure, function and pathogenicity. The FEBS journal. 2007 Aug;274(15):3799-845.
48. Moss BL, Schuetze SM. Development of rat soleus endplate membrane following denervation at birth. Journal of neurobiology. 1987 Jan;18(1):101-18.

49. Witzemann V, Chevessier F, Pacifici PG, Yampolsky P. The neuromuscular junction: selective remodeling of synaptic regulators at the nerve/muscle interface. Mechanisms of development. 2013 Jun 1;130(6-8):402-11
50. Fagerlund MJ, Dabrowski M, Eriksson LI. Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. The Journal of the American Society of Anesthesiologists. 2009 Jun 1;110(6):1244-52.
51. Van Rossum JM, Van Ras MT, Hurkmans JT, Hylkema MT. Classification and molecular pharmacology of ganglionic blocking agents Part I: Mechanism of ganglionic synaptic transmission and mode of action of ganglionic stimulants. International Journal of Neuropharmacology. 1962 Nov 1;1(1-3):97-110.
52. de Boer HD. Neuromuscular transmission: new concepts and agents. Journal of critical care. 2009 Mar 1;24(1):36-42.
53. Plaud B, Donati F. NEUROMUSCULAR BLOCKING AGENTS. On the Study and Practice of Intravenous Anaesthesia. 2013 Apr 17:207.
54. Dini? V, Vlatkovi? S, Markovi? D. AN UPDATE ON NEUROMUSCULAR JUNCTION PHYSIOLOGY AND PHARMACOLOGY. InEIGHTH ANNUAL SPRING SCIENTIFIC SYMPOSIUM IN ANESTHESIOLOGY AND INTENSIVE CARE 2017 Apr 21 (p. 85).
55. Fuchs-Buder T, Fuchs-Buder T. Chapter 1 Principles of neuromuscular transmission. Neuromuscular monitoring in clinical practice and research: Mit elnem Geleitwort von Robert Jütte. 2010:2-2.
56. Jonsson M. Nicotinic transmission and drugs in anesthesia: Neuromuscular blocking agents and propofol-consequences for carotid body function. Karolinska Institutet (Sweden); 2006.
57. Vélez PA, Lara-Erazo V, Caballero-Lozada AF, Botero A, Lozada G, Velásquez AF, Villegas LM, Zorrilla-Vaca A. Preoperative pregabalin prevents succinylcholine-induced fasciculation and myalgia: a meta-analysis of randomized trials. Revista Española de Anestesiología y Reanimación (English Edition). 2023 Sep 4.
58. Bickler PE, Abouyannis M, Bhalla A, Lewin MR. Neuromuscular weakness and paralysis produced by snakebite envenoming: mechanisms and proposed standards for clinical assessment. Toxins. 2023 Jan 6;15(1):49.
59. Farooq K, Hunter JM. Neuromuscular blocking agents and reversal agents. Anaesthesia & intensive care medicine. 2017 Jun 1;18(6):279-84.
60. Krenn M, Grisold A, Wohlfarth P, Rath J, Cetin H, Koneczny I, Zimprich F. Pathomechanisms and clinical implications of myasthenic syndromes exacerbated and induced by medical treatments. Frontiers in Molecular Neuroscience. 2020 Aug 14;13:156.
61. Yusuf S, Lonn E, Pais P, Bosch J, Lopez-Jaramillo P, Zhu J, Xavier D, Avezum A, Leiter LA, Piegas LS, Parkhomenko A. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. New England Journal of Medicine. 2016 May 26;374(21):2032-43.
62. Huang K, Luo YB, Yang H. Autoimmune channelopathies at neuromuscular junction. Frontiers in Neurology. 2019 May 17;10:451566.
63. Vernino S. Autoimmune and paraneoplastic channelopathies. Neurotherapeutics. 2007 Apr;4:305-14
64. Brenner T, Hamra?Amitay Y, Evron T, Boneva N, Seidman S, Soreq H. The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. The FASEB Journal. 2003 Feb;17(2):214-22.
65. Pitcher WD. Paralytic therapy and complications in the ICU
66. Keegan RD. Muscle relaxants and neuromuscular blockade. Veterinary Anesthesia and Analgesia: The Fifth Edition of Lumb and Jones. 2015 Apr 29:260-76.
67. Stewart PA, Liang SS, Li QS, Huang ML, Bilgin AB, Kim D, Phillips S. The impact of residual neuromuscular blockade, oversedation, and hypothermia on adverse respiratory events in a postanesthetic care unit: a prospective study of prevalence, predictors, and outcomes. Anesthesia & Analgesia. 2016 Oct 1;123(4):859-68.
68. Eikermann M, Santer P, Ramachandran SK, Pandit J. Recent advances in understanding and managing postoperative respiratory problems. F1000Research. 2019;8.
69. Sanders Jr RC, Daneshmand KA. ACUTE OR EXUDATIVE PHASE. Pediatric Critical Care Medicine. 2006;342(18):308.
70. EACHEMPATI SR. PRIORITIES IN THE ICU CARE OF THE ADULT TRAUMA PATIENT PHILIP S. BARIE AND. The Trauma Manual: Trauma and Acute Care Surgery. 2008:375.